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background:  The 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol treatment guidelines expand 
the indications and intensity of statin therapy for the prevention of cardiovascular disease. We assessed the treatment and cost implications 
of these new guidelines within a large cohort of active duty service members.
Methods:  Using the Department of Defense Military Health System (MHS) electronic health record, we examined 1000 randomly 
selected active duty persons ≥ 40 years of age. We recorded risk factors, to include measured lipid and blood pressure values, and active 
cholesterol treatment(s) prior to the 2013 ACC/AHA guidelines, and compared the recommended cholesterol treatment under the new ACC/
AHA guidelines versus the Third Adult Treatment Panel (ATP III) of the National Cholesterol Education Program. Costs for each treatment 
strategy were calculated using MHS pharmacy acquisition prices. Generic medications were assumed for any changes in lipid therapy to 
reach ATP-III goal or treatment according to the ACC/AHA guideline.
Results:  The mean age was 49 ± 7 years, 36% were female, 22% were on baseline statin therapy (4% high intensity), 13% were not at 
ATP III cholesterol goal, and 3% had a history of atherosclerotic cardiovascular disease. The mean 10-year ATP III risk was 3 ± 4% and the 
mean pooled cohort risk was 4 ± 4%. There was no difference in the proportion eligible for statin therapy between ATP III and ACC/AHA 
guidelines (31% versus 30%, respectively). Compared to ATP III, the recommended mean statin dose increased from 25 ± 20 mg to 36 ± 
25 mg (p<0.001) and the percentage of subjects eligible for high-intensity statin therapy increased from 6% to 11% (p<0.001) according to 
the ACC/AHA guideline. As compared to ATP III, statin treatment under the ACC/AHA guideline resulted in significantly higher estimated 
yearly statin acquisition costs, $40,197 versus $52,527 per 1000 patient-years (p<0.001).
conclusion:  Within a low-risk active duty population over 40 years of age, application of the 2013 ACC/AHA cholesterol treatment 
guidelines may not significantly increase those eligible for statins, but may increase statin treatment intensity and costs.
